Systemic Lupus Erythematosus Treatment Market - Top Companies and Manufacturers

Companies Dominating the Systemic Lupus Erythematosus Treatment Landscape

There is intense competition in the systemic lupus erythematosus treatment market, with major worldwide players including smaller and medium-sized businesses fighting for market share. A crucial aspect of marketing strategy involves the introduction of novel products that leverage diverse technology.

Anthera Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Aurinia Pharmaceuticals, Inc.
AstraZeneca plc
Biogen Inc.
GSK plc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
ImmuPharma PLC
Johnson & Johnson Services, Inc.
Novartis AG

Browse Key Market Insights with Data Illustration:

Systemic Lupus Erythematosus Treatment Market Size Forecasts 2037

In the News

In October 2022, Biogen Inc. reported that the first patient had been dosed in AMETHYST, a global clinical investigation. The Phase 2/3 study will compare litifilimab (also known as BIIB059), a first-in-class, humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2), to a placebo in participants with cutaneous lupus erythematosus (CLE).

In August 2021, AstraZeneca’s Saphnelo (anifrolumab-fnia) was licensed in the United States for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are currently receiving conventional therapy.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of systemic lupus erythematosus treatment was over USD 2.4 billion.

The market size for systemic lupus erythematosus treatment is projected to cross USD 6.1 billion by the end of 2037 expanding at a CAGR of 7.8% during the forecast period i.e., between 2025-2037.

The major players in the market are Anthera Pharmaceuticals, Inc., Aurinia Pharmaceuticals, Inc., AstraZeneca plc, Biogen Inc., GSK plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., ImmuPharma PLC, Johnson & Johnson Services, Inc., Novartis AG, and others.

The female segment is anticipated to garner a share/size of 60.2% during 2025-2037.

The North America systemic lupus erythematosus treatment sector is poised to hold 43.0% share by the end of 2037.

Systemic Lupus Erythematosus Treatment Market - Top Companies and Manufacturers

Companies Dominating the Systemic Lupus Erythematosus Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the systemic lupus erythematosus treatment industry?

What is the outlook for the systemic lupus erythematosus treatment market?

Who are the major players dominating the systemic lupus erythematosus treatment landscape?

Which segment will capture the significant market share for systemic lupus erythematosus treatment by 2037?

Which region will provide more opportunities for the systemic lupus erythematosus treatment business in the near future?